Why the study?
Non-adherence is a major challenge in hypertension management, and using drug concentrations can help identify non-adherence and optimize antihypertensive drug treatment.
What is the role of therapeutic drug monitoring in the treatment of hypertension?
What is the role of therapeutic drug monitoring in the treatment of hypertension?
Therapeutic drug monitoring may help identify non-adherence and optimize antihypertensive therapy in specific populations, despite traditional limitations in its application for these drugs.
May aid non-adherence detection via drug levels in hypertension; leaves open prospective outcome trials before routine use.
Antihypertensive drugs do not qualify as optimal candidates for therapeutic drug monitoring (TDM), given their obvious physiological effect, the absence of a clear relationship between drug concentrations and pharmacodynamic outcomes and their wide therapeutic range. However, since non-adherence is a major challenge in hypertension management, using drug concentrations can be of value to identify non-adherence as a first step towards better blood pressure control. In this article we discuss the key challenges associated with measuring and interpreting antihypertensive drug concentrations that are important when TDM is used to improve non-adherence. Additionally, we elaborate on the role of TDM in optimizing antihypertensive drug treatment besides addressing non-adherence by highlighting its value in specific patient groups with altered pharmacokinetic parameters such as female vs. male or elderly patients.
No takes yet. Share an insight, caveat, or question.
Versmissen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: